{"id":"W2903804915","doi":"10.1016/j.msard.2018.10.103","title":"Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive Multiple Sclerosis Treated with Ocrelizumab in the Open-label Extension Period of the Phase III ORATORIO trial","year":2018,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ocrelizumab; Medicine; Multiple sclerosis; Placebo; Myelofibrosis; Oratorio; Open label; Internal medicine; Clinical trial; Immunology; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001034244,0.0004864804,0.0009307521,0.0002472427,0.0004767617,0.00009821171,0.0004163516,0.0002856443,0.00002301036],"category_scores_gemma":[0.0009141488,0.0002419775,0.00007813387,0.002104162,0.002277803,0.0003848313,0.0004001517,0.0007388009,8.489815e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003806057,"about_ca_system_score_gemma":0.0002437159,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001374642,"about_ca_topic_score_gemma":0.001915732,"domain_scores_codex":[0.9955586,0.0007781229,0.001013284,0.0009612638,0.0009733735,0.0007153503],"domain_scores_gemma":[0.9977949,0.0002862836,0.0004863196,0.0008193028,0.0004704165,0.0001428365],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2119836,0.01556127,0.7092562,0.0001576679,0.0001515106,0.000005392364,0.006032065,0.0000239754,0.004834808,0.000005251467,0.00007130329,0.05191692],"study_design_scores_gemma":[0.3007476,0.005096151,0.6862662,0.001895249,0.00006600161,0.000001939039,0.003952412,0.001197572,0.0005063384,0.000005752491,0.00001874526,0.00024599],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860179,0.0003962799,0.00000263759,0.001060109,0.000100645,0.012208,0.00003273232,0.00003667269,0.0001450033],"genre_scores_gemma":[0.9982862,0.000302949,0.0001858589,0.00003301073,0.00002972531,0.0009763705,0.0001135024,0.00005397595,0.00001844242],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08876406,"threshold_uncertainty_score":0.9867555,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04062952160412597,"score_gpt":0.3035690542692676,"score_spread":0.2629395326651416,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}